Please wait...
GulfBase Live Support
- Jamjoom Pharma enters deal with Bio-Thera for Cosentyx biosimilar
- Adnoc L&S uses AI to optimise operations at UAE petroleum ports
- Al Majdiah awards contracts for two residential projects
- Fujitec Saudi Arabia wins Naba AlSaha Hospital contract
- Al-Futtaim buys 49.95% stake in Cenomi Retail for $686m
- ALEC Holdings launches IPO; ICD offers 20% stake
- Dollar Sukuk: Saudi Banks' Strategy to Attract Foreign Investors
- Energy official urges balanced transition for sustainable future
- Central Bank of Oman launches national payment card 'Maal'
- Oman's natural gas output hits 32.9bn cubic metres in first 7 months of 2025
16/09/2025 07:55 AST
Jamjoom Pharmaceuticals Factory Company (Jamjoom Pharma), one of the fastest-growing pharmaceutical companies in the Middle East and Africa, has signed a strategic commercialisation agreement with Bio-Thera Solutions, a global biopharmaceutical company specialising in innovative therapies and biosimilars.
Under the agreement, Jamjoom Pharma will obtain the exclusive rights to commercialise BAT2306 - a proposed biosimilar to Novartis' Cosentyx (secukinumab) - across the Middle East and North Africa (MENA) region.
Cosentyx is a biologic medication used to treat conditions like psoriasis, psoriatic arthritis, and ankylosing spondylitis.
Jamjoom Pharma will manage regulatory submissions, market access, and commercialisation in MENA, while Bio-Thera will oversee product development and global manufacturing from its state-of-the-art facilities in Guangzhou, China.
"This collaboration is a strategic milestone for Jamjoom Pharma and a testament to our mission of broadening access to advanced biologics in the MENA region," said Tarek Hosni, Chief Executive Officer of Jamjoom Pharma. "By joining forces with Bio-Thera, we are combining world-class biosimilar development with Jamjoom's deep regional expertise, strong commercial capabilities, and commitment to delivering high-quality, affordable therapies. This agreement strengthens our leadership in the biopharmaceutical sector and reinforces our role as a trusted partner in improving patient outcomes."
"Bio-Thera is committed to bringing affordable medicines to patients in need around the world, " said Bert Thomas, Senior Vice President of Business Development.
"Partnering with JamJoom Pharma to bring BAT2306 to patients in the MENA region is a demonstration of that commitment. We are proud to partner with Jamjoom Pharma and look forward to a successful collaboration," Thomas said.
Trade Arabia
| Ticker | Price | Volume |
|---|
| Ticker | Price | Change |
|---|---|---|
| SPIMACO | 27.06 | 0.04 (0.14 |
| AVALONPHARMA | 121.00 | -2.00 (-1.63 |
16/09/2025
Adnoc Logistics and Services (Adnoc L&S) has deployed the first AI-powered Smart Port Solution in the GCC to optimise petroleum port operations.
The solution streamlines resource allocation
Trade Arabia
16/09/2025
Dar Al Majdiah Real Estate Company (Al Majdiah) has signed two contracts with Tatweej Contracting Company to implement two residential projects - one each in Riyadh and Jeddah - as part of the compan
Trade Arabia
16/09/2025
Saudi Arabia's Naba Alsaha Medical Services Company has awarded a contract to Fujitec Saudi Arabia for the supply and installation of elevators and escalators for the Naba AlSaha Hospital project in
Trade Arabia
16/09/2025
Al-Futtaim, a regional retail powrhouse, has acquired a 49.95% stake in Cenomi Retail, a leading retail brand in Saudi Arabia, for a total consideration of SAR2.52 billion ($686 million), at SAR44 pe
Trade Arabia
16/09/2025
ALEC Holdings, a market-leading diversified engineering and construction group, today announced its intention to list 20% of its share capital on the Dubai Financial Market (DFM) through an initial p
Trade Arabia
Financial Information Co.
P.O. Box 69410, Jeddah 11547, Saudi Arabia